Search

Illumina Inc

Fermé

SecteurSoins de santé

269.35 -0.41

Résumé

Variation du prix de l'action

24h

Actuel

Min

268.35

Max

271.41

Chiffres clés

By Trading Economics

Revenu

-268M

-134M

Ventes

68M

1.2B

P/E

Moyenne du Secteur

49.004

49.241

BPA

1.31

Marge bénéficiaire

-11.562

Employés

8,600

EBITDA

80M

330M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-7.53% downside

Dividendes

By Acuity

Prochains Résultats

29 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

11B

40B

Ouverture précédente

269.76

Clôture précédente

269.35

Illumina Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 oct. 2026, 23:26 UTC

Illumina Inc shares advanced modestly higher in after-market hours on Friday, recovering from a slight decline following the regular session's close.

22 oct. 2026, 23:06 UTC

Illumina Inc shares are modestly higher in after-market trading, remaining stable around the midpoint of their one-month trading range.

21 oct. 2026, 23:06 UTC

Illumina Inc's shares advanced in after-market trading on Wednesday, remaining above its 20-day moving average and near the upper end of its one-month range.

20 oct. 2026, 20:08 UTC

Illumina Inc shares are trading higher compared to Monday's close, having reached a peak earlier in the session before pulling back slightly.

19 oct. 2026, 20:01 UTC

News

Canaccord analyst Kyle Mikson raised Illumina's price target to $300.00 from $205.00 while maintaining a Hold rating.

17 oct. 2026, 00:01 UTC

Illumina Inc's shares are declining in after-market trading, reversing an earlier gain and remaining significantly below their 20-day moving average.

16 oct. 2026, 23:41 UTC

Illumina Inc shares declined during after-market hours, continuing a downward trend over three sessions and remaining significantly below the 20-day moving average.

15 oct. 2026, 23:06 UTC

Illumina Inc's shares rose in after-market trading, recovering from an initial dip to peak before settling slightly lower.

14 oct. 2026, 20:07 UTC

News

Illumina Inc launched the BioInsight Platform, enhancing genomic research with integrated AI tools and updated DRAGEN v4.6 software for cloud and CPU environments.

13 oct. 2026, 20:01 UTC

News

TD Cowen analyst Dan Brennan raised Illumina's price target to $270 from $210 while maintaining a Hold rating, despite the stock declining in today's session.

12 oct. 2026, 23:21 UTC

Illumina Inc shares declined in after-market hours, shifting from a slight gain to a loss, amid notable declines in trading.

9 oct. 2026, 20:01 UTC

Illumina Inc shares are sharply higher, diverging from their recent trend of higher daily closes since Thursday's close amid a broader market backdrop.

8 oct. 2026, 23:05 UTC

Illumina Inc shares are lower in after-market hours, following a slight dip earlier in the session.

7 oct. 2026, 19:53 UTC

News

Illumina Inc shares fell sharply today as Barclays maintained its Underweight rating but raised its price target to $200 from $160.

6 oct. 2026, 23:20 UTC

Illumina Inc is trading modestly higher in after-market hours, reaching a peak near the upper end of its one-month range and above its 20-day moving average.

5 oct. 2026, 20:01 UTC

News

Illumina Inc shares rise sharply as RBC Capital raises the price target to $310 from $230 while maintaining an Outperform rating.

2 oct. 2026, 23:26 UTC

Illumina Inc is seeing a slight decline in after-market trading, following a strong one-month performance near the upper end of its recent range.

1 oct. 2026, 23:41 UTC

Illumina Inc's shares advanced modestly higher in after-market trading, maintaining a position well above its 20-day moving average despite retracing from an earlier high.

30 sept. 2026, 23:40 UTC

Illumina Inc is advancing in after-market trading, moving higher alongside the broader market, following notable volatility and positive U.S. GDP growth data revisions.

29 sept. 2026, 23:01 UTC

Illumina Inc is seeing a modest rise in after-market trading, reaching its highest level since Tuesday and remaining above its 20-day moving average.

28 sept. 2026, 19:16 UTC

News

Piper Sandler raised Illumina's price target to $305.00 from $225.00, maintaining an Overweight rating as shares trade roughly flat since Friday.

25 sept. 2026, 23:05 UTC

Illumina Inc's shares traded modestly lower in after-market hours, following a decline from earlier highs, despite strong gains over the past month.

24 sept. 2026, 23:06 UTC

Social Media

Illumina Inc is declining in after-market hours after retracing from an earlier peak, despite a recent strong performance above its 20-day moving average.

23 sept. 2026, 23:01 UTC

Social Media

Illumina Inc is seeing notable after-market gains following commentary on a new gene-editing mechanism, reflecting volatility after an initial dip earlier in the session.

22 sept. 2026, 20:06 UTC

Illumina Inc is advancing, continuing its upward trajectory since Monday, peaking in the late afternoon and remaining above the 20-day moving average.

21 sept. 2026, 20:06 UTC

Illumina Inc shares fell modestly after a mid-morning peak, though they remain above the 20-day moving average and near the upper end of their one-month range.

18 sept. 2026, 23:06 UTC

Illumina Inc's stock is advancing in after-market trading, supported by mixed economic data and remaining above its 20-day moving average.

17 sept. 2026, 23:06 UTC

Illumina Inc is trading modestly higher in after-market hours, supported by strong broader market performance and recent gains over the past month.

16 sept. 2026, 23:01 UTC

Illumina Inc. is up in after-market trading, following five consecutive sessions of gains and trading significantly above its 20-day moving average.

15 sept. 2026, 23:01 UTC

Illumina Inc's shares are trading higher in after-market hours, benefiting from a broader market rally despite mixed macroeconomic signals.

Comparaison

Variation de prix

Illumina Inc prévision

Objectif de Prix

By TipRanks

-7.53% baisse

Prévisions sur 12 Mois

Moyen 249.125 USD  -7.53%

Haut 320 USD

Bas 113 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

16 ratings

9

Achat

4

Maintien

3

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
help-icon Live chat